These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Sensitivity of three activated partial thromboplastin time reagents to coagulation factor deficiencies. Turi DC; Peerschke EI Am J Clin Pathol; 1986 Jan; 85(1):43-9. PubMed ID: 3940420 [TBL] [Abstract][Full Text] [Related]
26. Multicenter evaluation of a chromogenic substrate method for photometric determination of prothrombin time. Dati F; Barthels M; Conard J; Flückiger J; Girolami A; Hänseler E; Huber J; Keller F; Kolde HJ; Müller-Berghaus G Thromb Haemost; 1987 Oct; 58(3):856-65. PubMed ID: 3433249 [TBL] [Abstract][Full Text] [Related]
27. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031 [TBL] [Abstract][Full Text] [Related]
28. Relation of simple clotting tests to clotting factor levels in liver disease. Ruiz F; Grainger SL; Hall RJ; Ingram GI; Pollard V; Swan AV Clin Lab Haematol; 1982; 4(3):247-56. PubMed ID: 7172607 [TBL] [Abstract][Full Text] [Related]
30. Should healthy children who will undergo minor surgery be screened for coagulation disorder? Kang S; Yoon HS; Lee EH Pediatr Hematol Oncol; 2016 May; 33(4):233-8. PubMed ID: 27166650 [TBL] [Abstract][Full Text] [Related]
31. Use of the activated partial thromboplastin time for the diagnosis of congenital coagulation disorders: problems and possible solutions. Barna L; Triplett DA Ric Clin Lab; 1989; 19(4):345-54. PubMed ID: 2517350 [TBL] [Abstract][Full Text] [Related]
32. Blood clotting disorders during experimental sarcocystiosis in calves. Daugschies A; Rupp U; Rommel M Int J Parasitol; 1998 Aug; 28(8):1187-94. PubMed ID: 9762563 [TBL] [Abstract][Full Text] [Related]
34. Automated prothrombin-time test with use of a chromogenic peptide substrate and a centrifugal analyzer. Becker U; Jering H; Bartl K; Jilek F Clin Chem; 1984 Apr; 30(4):524-8. PubMed ID: 6705195 [TBL] [Abstract][Full Text] [Related]
35. [Importance of Quick, partial thromboplastin time, and Co]. Siegert G Internist (Berl); 2014 May; 55(5):506, 508, 510-3. PubMed ID: 24781934 [TBL] [Abstract][Full Text] [Related]
36. Causes of isolated prolonged activated partial thromboplastin time in an acute care general hospital. Chng WJ; Sum C; Kuperan P Singapore Med J; 2005 Sep; 46(9):450-6. PubMed ID: 16123828 [TBL] [Abstract][Full Text] [Related]
37. Underestimation of plasma level of factor V coagulant activity and fibrinogen concentration together with prolonged prothrombin time, activated partial thromboplastin time and thrombin time can result from pre-analytical very low calcium level in citrated sample tube. d'Audigier C; Delassasseigne C; Robert A; Eschwège V Int J Lab Hematol; 2016 Feb; 38(1):50-3. PubMed ID: 26406495 [TBL] [Abstract][Full Text] [Related]
38. Detection of mild factor VIII Deficiency by thrombokinetics. Natelson EA; Shapiro D; Smith DF Am J Clin Pathol; 1975 Jul; 64(1):95-100. PubMed ID: 1155379 [TBL] [Abstract][Full Text] [Related]
39. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Kamal AH; Tefferi A; Pruthi RK Mayo Clin Proc; 2007 Jul; 82(7):864-73. PubMed ID: 17605969 [TBL] [Abstract][Full Text] [Related]
40. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time. Burns ER; Goldberg SN; Wenz B Am J Clin Pathol; 1993 Aug; 100(2):94-8. PubMed ID: 8356955 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]